Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 15-23
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15
Table 1 Baseline characteristics of patients in the two groups
Group | Gender (male/female) | Age (yr) | Average age (yr) | Primary lesion site (n) | Metastasis site (n) | ||||
Left-sided colorectal | Right-sided colon | Liver | Bone | Lung | Abdominal cavity | ||||
Observation group (n = 47) | 23/24 | 60-83 | 72.25 ± 6.41 | 31 | 16 | 19 | 12 | 11 | 5 |
Control group (n = 47) | 22/25 | 60-82 | 72.19 ± 6.37 | 30 | 17 | 18 | 13 | 10 | 6 |
Table 2 Recent therapeutic effects in the two groups
Group | CR | PR | SD | PD | DCR |
Observation group (n = 47) | 0 | 11 (23.40) | 17 (36.17) | 19 (40.43) | 28 (59.57) |
Control group (n = 47) | 0 | 10 (21.28) | 16 (34.04) | 21 (44.68) | 26 (55.32) |
χ2 | 0.174 | ||||
P value | 0.677 |
Table 3 Incidence of adverse reactions during treatment in the two groups
Group | HFSR | Anemia | Hepatic insufficiency | Weakness | Nausea and vomiting | Neutropenia |
Observation group (n = 47) | 10 (21.28) | 2 (4.26) | 2 (4.26) | 7 (14.89) | 14 (29.79) | 14 (29.79) |
Control group (n = 47) | 9 (19.15) | 1 (2.13) | 2 (4.26) | 5 (10.64) | 12 (25.53) | 12 (25.53) |
χ2 | 0.066 | 0 | 0.261 | 0.382 | 0.213 | 0.213 |
P value | 0.797 | 1 | 0.609 | 0.536 | 0.645 | 0.645 |
Table 4 Levels of serum carcinoembryonic antigen, carbohydrate antigen 199, carbohydrate antigen 125 in the two groups
Group | CEA (μg/mL) | CA199 (U/mL) | CA125 (U/mL) | |||
Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
Observation group (n = 47) | 8.22 ± 0.76 | 1.53 ± 0.12a | 50.63 ± 4.75 | 20.67 ± 2.01a | 72.90 ± 7.04 | 43.09 ± 5.63a |
Control group (n = 47) | 8.35 ± 0.71 | 3.91 ± 0.19a | 51.22 ± 4.92 | 39.54 ± 2.76a | 72.83 ± 7.12 | 45.13 ± 6.97a |
χ2 | 0.857 | 72.607 | 0.591 | 37.889 | 0.038 | 2.247 |
P value | 0.3197 | < 0.001 | 0.278 | < 0.001 | 0.97 | 0.0217 |
- Citation: Zhou DB, Cheng J, Zhang XH. Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis. World J Clin Cases 2024; 12(1): 15-23
- URL: https://www.wjgnet.com/2307-8960/full/v12/i1/15.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.15